10-летний опыт лечения фиброзной дисплазии челюстно-лицевой области препаратами алендроновой кислоты

Фиброзная дисплазия (ФД) – редкое доброкачественное гамартомное заболевание костей, характеризующееся соединением фиброзных костных элементов в очаге. В связи с отсутствием общепринятого универсального подхода к лечению ФД хирургическое лечение остается предпочтительным, однако в случае малых очагов или субтотального поражения костей хирургический метод нерационален или невозможен. Накопленный зарубежный и наш собственный опыт консервативного лечения пациентов препаратами бисфосфонатного ряда расширяет возможности выбора тактики лечения пациентов с данной врожденной патологией. При использовании бисфосфонатных препаратов не отмечено развития серьезных побочных реакций, а в ряде случаев удалось избежать оперативного лечения.

1. Assaf A.T., Benecke A.W., Riecke B., Zustin J., Fuhrmann A.W., Heiland M., et al. Craniofacial fibrous dysplasia (CFD) of the maxilla in an 11-year old boy: A case report. J Craniomaxillofac Surg 2012; 40: 788–92.

2. Волков М.В. Фиброзная остеодисплазия. – М., 1973.

3. Feller L., Wood N.H., Khammissa R.A., Lemmer J., Raubenheimer E.J. The nature of fibrous dysplasia. Head Face Med 2009; 5: 22–7.

4. Tabrizi R., Ozkan B.T. Craniofacial fibrous dysplasia of orbit. J Craniofac Surg 2008; 19: 1532–7.

5. Keskin M., Karabekmez F.E., Ozkan B.T., Tosun Z., Avunduk M.C., Savaci N. Simultaneous occurrence of facial fibrous dysplasia and ameloblastoma. J Craniomaxillofac Surg 2009; 37: 102–5.

6. Nadaf A., Radhika M., Paremala K., Srinath N. Monostostic fibrous dysplasia with nonspecific cystic degeneration:A case report and review of literature. J Oral Maxillofac Pathol 2013 May; 17 (2): 274–80.

7. Valentini V., Cassoni A., Marianetti T.M., Terenzi V., Fadda M.T., Iannetti G. Craniomaxillofacial fibrous dysplasia: Conservative treatment or radical surgery? A retrospective study on 68 patients. Plast Reconstr Surg 2009; 123: 653–60.

8. Kim D.D., Ghali G.E., Wright J.M., Edwards S.P. Surgical treatment of giant fibrous dysplasia of the mandible with concomitant craniofacial involvement. J Oral Maxillofac Surg 2012; 70:102–18.

9. Delozier J.B., Egger M.E., Bottomy M.B. Infantile fibrous dysplasia of the mandible. J Craniofac Surg 2004 Nov; 15 (6): 1039–43.

10. Eversole L.R., Sabes W.R., Rovin S. Fibrous dysplasia: A nosologic problem in the diagnosis of fibro osseous lesions of the jaws. J Oral Pathol 1972; 1: 189.

11. Kabukcuoglu F., Kabukcuoglu Y. Mazabraud's syndrome: Intramuscular myxoma associated with fibrous dysplasia. Orphanet Encyclopedia. 2005. [Last accessed on 2010 Dec 21]; pp. 1–4. Available from: https://www.orpha.net/data/patho/GB/uk-Mazabraud.pdf

12. Charpurlat R.D., Meunier P.J. Fibrous dysplasia of bone. Bailliere's Clin Rheumatol 2000; 14: 385–98.

13. Lala R., Matarazzo P., Andreo M., Defilippi C., de Sanctis C. Impact of endocrine hyperfunction and phosphate wasting on bone in McCune-Albright syndrome. J Pediatr Endocrinol Metab 2002; 15 (Suppl 3): 913–20.

14. Boyce A.M., Chong W.H., Yao J., Kelly M.H., Chamberlain C.E., Bassim C., et al. Denosumab treatment for fibrous dysplasia. J Bone Miner Res 2012;in press.

15. Park B.Y., Cheon Y.W., Kim Y.O., Pae N.S., Lee W.J. Prognosis for craniofacial fibrous dysplasia after incomplete resection: AGE and serum alkaline phosphatise. Int J Oral Maxillofac Surg 2010; 39: 221–6.

16. Chapurlat R.D., Hugueny P., Delmas P.D., Meunier P.J. Treatment of fibrous dysplasia of bone with intravenous pamidronate: long-term effectiveness and evaluation of predictors of response to treatment. Bone 2004; 35 (1): 235–42.

17. Bachrach L.K., Ward L.M. Clinical review: bisphosphonate use in childhood osteoporosis. Journal of Clinical Endocrinology and Metabolism 2009; 94 (2): 400–9.

18. Kitagawa Y., Tamai K., Ito H. Oral alendronate treatment for polyostotic fibrous dysplasia: a case report. Journal of Orthopaedic Science 2004; 9 (5): 521–5.

19. Ana Luiza A.A., Ivani N.S. Oral alendronate treatment for severe polyostotic fibrous dysplasia due to McCune-Albright syndrome in a child: A case report International Journal of Pediatric Endocrinology 2010; Аrticle ID 432060: 1–4.

20. Diaz A., Danon M., Crawford J. McCune-Albright syndrome and disorders due to activating mutations of GNAS1. Journal of Pediatric Endocrinology and Metabolism 2007: 20 (8): 853–80.

21. Thomsen M.D., Rejnmark L.Clinical and radiological observations in a case series of 26 patients with fibrous dysplasia. Calcif Tissue Int 2014 Apr; 94 (4): 384–95.

22. Ngan K.K., Bowe J., Goodger N. The risk of bisphosphonate-related osteonecrosis of the jaw in children. A case report and literature review. Dent Update 2013 Nov; 40 (9): 733–4, 736–8.

23. Lietman S.A., Schwindinger W.F., Levine M.A. Genetic and molecular aspects of McCune-Albright syndrome. Pediatr Endocrinol Rev 2007; 4 (suppl 4): 380–5.

24. Lv M., Li X., Huang Y., Wang N., Zhu X., Sun J. Inhibition of fibrous dysplasia via blocking Gs with suramin sodium loaded with an alendronate-conjugated polymeric drug delivery system. Biomater Sci 2016 Jul 21; 4 (7): 1113–22.